CAS: 877950-01-1

LtaS-IN-1

LtaS-IN-1 inhibits LTA synthesis in MDR E. faecium; alters cell walls; MIC: 0.5-64 μg/mL for 28 Enterococcus strains.

LTAS-IN-1 is a synthetic chemical compound designed as an advanced inhibitor, which is developed through a series of intricate chemical synthesis processes. The mode of action of LTAS-IN-1 involves the selective inhibition of specific enzyme targets, effectively modulating their biological pathways. This selective inhibition allows researchers to investigate the compound's effects on various cellular and molecular processes. The primary uses and applications of LTAS-IN-1 are concentrated in the field of biomedical research. Scientists employ this compound to study disease mechanisms, particularly those related to aberrant enzyme activity. By analyzing the compound's impact on cellular systems, researchers can uncover insights into potential therapeutic interventions for conditions where enzyme dysregulation is implicated. Moreover, LTAS-IN-1 serves as a critical tool in drug discovery and development programs, facilitating the screening and characterization of novel drug candidates that target similar biochemical pathways. The compound's applications extend to preclinical studies, where it is utilized to explore its efficacy, safety, and mechanism-based interactions with biological molecules. Through its intricate mode of action and versatile applications, LTAS-IN-1 remains an essential component in the toolkit of scientific inquiries aimed at understanding and treating complex diseases.